evaluated the combination of immunotherapy (IL-21) and β-cell-directed treatment (liraglutide) in a randomized, double-blind and phase 2 trial in 308 adults with new-onset T1D (129). The gene discussed is IL21; the disease is type 1 diabetes mellitus.